171 related articles for article (PubMed ID: 20114046)
1. Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice.
Wouters K; van Bilsen M; van Gorp PJ; Bieghs V; Lütjohann D; Kerksiek A; Staels B; Hofker MH; Shiri-Sverdlov R
FEBS Lett; 2010 Mar; 584(5):1001-5. PubMed ID: 20114046
[TBL] [Abstract][Full Text] [Related]
2. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
Cong WN; Tao RY; Tian JY; Liu GT; Ye F
Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibition of adipocyte fatty acid binding protein alleviates both acute liver injury and non-alcoholic steatohepatitis in mice.
Hoo RL; Lee IP; Zhou M; Wong JY; Hui X; Xu A; Lam KS
J Hepatol; 2013 Feb; 58(2):358-64. PubMed ID: 23108115
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis.
Beraza N; Malato Y; Vander Borght S; Liedtke C; Wasmuth HE; Dreano M; de Vos R; Roskams T; Trautwein C
Gut; 2008 May; 57(5):655-63. PubMed ID: 18408102
[TBL] [Abstract][Full Text] [Related]
5. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice.
Zheng S; Hoos L; Cook J; Tetzloff G; Davis H; van Heek M; Hwa JJ
Eur J Pharmacol; 2008 Apr; 584(1):118-24. PubMed ID: 18329014
[TBL] [Abstract][Full Text] [Related]
6. Animal models of non-alcoholic steatohepatitis: of mice and man.
Schattenberg JM; Galle PR
Dig Dis; 2010; 28(1):247-54. PubMed ID: 20460919
[TBL] [Abstract][Full Text] [Related]
7. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.
Ota T; Takamura T; Kurita S; Matsuzawa N; Kita Y; Uno M; Akahori H; Misu H; Sakurai M; Zen Y; Nakanuma Y; Kaneko S
Gastroenterology; 2007 Jan; 132(1):282-93. PubMed ID: 17241878
[TBL] [Abstract][Full Text] [Related]
8. Hyperlipidemic chicken as a model of non-alcoholic steatohepatitis.
Ayala I; Castillo AM; Adánez G; Fernández-Rufete A; Pérez BG; Castells MT
Exp Biol Med (Maywood); 2009 Jan; 234(1):10-6. PubMed ID: 18997102
[TBL] [Abstract][Full Text] [Related]
9. Serotonin mediates oxidative stress and mitochondrial toxicity in a murine model of nonalcoholic steatohepatitis.
Nocito A; Dahm F; Jochum W; Jang JH; Georgiev P; Bader M; Renner EL; Clavien PA
Gastroenterology; 2007 Aug; 133(2):608-18. PubMed ID: 17681180
[TBL] [Abstract][Full Text] [Related]
10. Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates.
Shiri-Sverdlov R; Wouters K; van Gorp PJ; Gijbels MJ; Noel B; Buffat L; Staels B; Maeda N; van Bilsen M; Hofker MH
J Hepatol; 2006 Apr; 44(4):732-41. PubMed ID: 16466828
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model.
Sahai A; Malladi P; Melin-Aldana H; Green RM; Whitington PF
Am J Physiol Gastrointest Liver Physiol; 2004 Jul; 287(1):G264-73. PubMed ID: 15044174
[TBL] [Abstract][Full Text] [Related]
12. Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation.
Larter CZ; Yeh MM; Cheng J; Williams J; Brown S; dela Pena A; Bell-Anderson KS; Farrell GC
J Gastroenterol Hepatol; 2008 Feb; 23(2):267-75. PubMed ID: 17868330
[TBL] [Abstract][Full Text] [Related]
13. Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet.
Koppe SW; Sahai A; Malladi P; Whitington PF; Green RM
J Hepatol; 2004 Oct; 41(4):592-8. PubMed ID: 15464239
[TBL] [Abstract][Full Text] [Related]
14. Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease.
Hong XZ; Li LD; Wu LM
Clin Exp Pharmacol Physiol; 2007; 34(1-2):27-35. PubMed ID: 17201732
[TBL] [Abstract][Full Text] [Related]
15. Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression.
Farrell GC; Larter CZ; Hou JY; Zhang RH; Yeh MM; Williams J; dela Pena A; Francisco R; Osvath SR; Brooling J; Teoh N; Sedger LM
J Gastroenterol Hepatol; 2009 Mar; 24(3):443-52. PubMed ID: 19226377
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome.
Van Rooyen DM; Gan LT; Yeh MM; Haigh WG; Larter CZ; Ioannou G; Teoh NC; Farrell GC
J Hepatol; 2013 Jul; 59(1):144-52. PubMed ID: 23500152
[TBL] [Abstract][Full Text] [Related]
17. The role of the lipogenic pathway in the development of hepatic steatosis.
Postic C; Girard J
Diabetes Metab; 2008 Dec; 34(6 Pt 2):643-8. PubMed ID: 19195625
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-10 is a protective factor against diet-induced insulin resistance in liver.
Cintra DE; Pauli JR; Araújo EP; Moraes JC; de Souza CT; Milanski M; Morari J; Gambero A; Saad MJ; Velloso LA
J Hepatol; 2008 Apr; 48(4):628-37. PubMed ID: 18267346
[TBL] [Abstract][Full Text] [Related]
19. Non-alcoholic steatohepatitis in children.
Nanda K
Pediatr Transplant; 2004 Dec; 8(6):613-8. PubMed ID: 15598336
[TBL] [Abstract][Full Text] [Related]
20. Prevention and reversal of lipotoxicity-induced hepatic insulin resistance and steatohepatitis in mice by an antioxidant carotenoid, β-cryptoxanthin.
Ni Y; Nagashimada M; Zhan L; Nagata N; Kobori M; Sugiura M; Ogawa K; Kaneko S; Ota T
Endocrinology; 2015 Mar; 156(3):987-99. PubMed ID: 25562616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
